title: Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH.
abstract: OBJECTIVE
  The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after single intravenous administrations of lansoprazole 30 mg and famotidine 20 mg.
  
  
  METHODS
  Twelve Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 4 hours after single intravenous administration of lansoprazole 30 mg or famotidine 20 mg.
  
  
  RESULTS
  The average pH during the 4-hour period after administration of famotidine was higher than after lansoprazole (median: 5.15 versus 3.55, respectively; p = 0.0376). During the 4-hour study period, famotidine 20 mg provided a longer duration of pH > 3, 3.5, 4, 5, 6 and 7, compared to lansoprazole 30 mg (median: 73.6% versus 57.0%; p = 0.0414, 66.8% versus 47.8%; p = 0.0281, 60.8% versus 38.8%; p = 0.0150, 55.7% versus 29.7%; p = 0.0281, 45.0% versus 23.1%; p = 0.0414 and 23.9% versus 3.65%; p = 0.0076).
  
  
  CONCLUSIONS
  In Helicobacter pylori-negative healthy male subjects, an intravenous dose of famotidine 20 mg more rapidly increases intragastric pH than lansoprazole 30 mg.
authors: Gastroenterology Division, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama Kanagawa, 236-0004, Japan.
authors: Hiroshi
authors: H
authors: Iida
authors: Masahiko
authors: M
authors: Inamori
authors: Keiko
authors: K
authors: Akimoto
authors: Hironori
authors: H
authors: Mawatari
authors: Hiroki
authors: H
authors: Endo
authors: Yuichi
authors: Y
authors: Nozaki
authors: Tomoyuki
authors: T
authors: Akiyama
authors: Tamon
authors: T
authors: Ikeda
authors: Yasunari
authors: Y
authors: Sakamoto
authors: Koji
authors: K
authors: Fujita
authors: Kyoko
authors: K
authors: Yoneda
authors: Hirokazu
authors: H
authors: Takahashi
authors: Masato
authors: M
authors: Yoneda
authors: Ayumu
authors: A
authors: Goto
authors: Yasunobu
authors: Y
authors: Abe
authors: Noritoshi
authors: N
authors: Kobayashi
authors: Hiroyuki
authors: H
authors: Kirikoshi
authors: Kensuke
authors: K
authors: Kubota
authors: Satoru
authors: S
authors: Saito
authors: Atsushi
authors: A
authors: Nakajima
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D018592:Cross-Over Studies; D065731:Cytochrome P-450 CYP2C19; D015738:Famotidine / Q000008:administration & dosage*; D005744:Gastric Acid / Q000378:metabolism*; D005838:Genotype; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D064747:Lansoprazole; D008297:Male; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D015738:Famotidine; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19